BAWEI
837023
Yili Chuanning Biotechnology
301301
Shanghai Menon Animal Nutrition Technology
301156
4
Tongling Jieya Biologic Technology
301108
5
XI'AN WONDER
836419
(Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 69.00%360.06M | 28.35%1.05B | 16.54%305.44M | 61.10%313.48M | 25.27%222.03M | 13.75%213.06M | 4.53%821.21M | 24.74%262.09M | 6.33%194.58M | -13.17%177.24M |
Operating revenue | 69.00%360.06M | 28.35%1.05B | 16.54%305.44M | 61.10%313.48M | 25.27%222.03M | 13.75%213.06M | 4.53%821.21M | 24.74%262.09M | 6.33%194.58M | -13.17%177.24M |
Cost of revenue | 42.74%247.36M | -0.21%731.17M | -13.95%195.27M | 11.23%189.96M | 8.42%172.65M | -1.41%173.29M | 2.03%732.72M | 21.04%226.94M | -11.20%170.79M | -10.87%159.23M |
Gross profit | 183.42%112.7M | 264.84%322.84M | 213.40%110.18M | 419.07%123.52M | 174.29%49.38M | 244.77%39.77M | 31.13%88.49M | 55.31%35.16M | 354.83%23.8M | -29.34%18M |
Operating expense | 32.29%38.33M | 47.98%107.39M | 71.70%15.38M | 33.19%34.77M | 68.45%28.27M | 39.78%28.97M | 9.81%72.57M | -49.40%8.96M | 43.99%26.1M | 15.21%16.78M |
Selling and administrative expenses | -3.42%13.91M | 14.71%47.73M | 8.76%11.12M | 15.29%10.97M | 14.83%11.24M | 19.21%14.4M | 5.44%41.61M | 0.41%10.22M | -2.16%9.51M | 5.41%9.79M |
-General and administrative expense | -3.42%13.91M | 14.71%47.73M | 8.76%11.12M | 15.29%10.97M | 14.83%11.24M | 19.21%14.4M | 5.44%41.61M | 0.41%10.22M | -2.16%9.51M | 5.41%9.79M |
Other operating expenses | 67.60%24.41M | 92.68%59.66M | 437.26%4.26M | 43.46%23.8M | 143.50%17.03M | 68.54%14.57M | 16.29%30.96M | -116.81%-1.26M | 97.36%16.59M | 32.47%6.99M |
Operating profit | 588.99%74.38M | 1,253.28%215.46M | 261.84%94.8M | 3,948.74%88.75M | 1,629.07%21.11M | 217.44%10.8M | 1,040.47%15.92M | 430.86%26.2M | 91.60%-2.31M | -88.81%1.22M |
Net non-operating interest income expense | 19.29%-10.45M | -76.21%-51.28M | -60.72%-11.89M | -79.41%-13.28M | -90.42%-13.16M | -75.22%-12.95M | -21.95%-29.1M | 9.71%-7.4M | -24.78%-7.4M | -33.69%-6.91M |
Non-operating interest expense | -19.95%9.87M | 85.36%48.92M | 69.99%11.31M | 89.57%12.7M | 100.02%12.58M | 82.66%12.33M | 21.01%26.39M | -12.34%6.65M | 24.12%6.7M | 34.60%6.29M |
Total other finance cost | -6.14%581K | -12.88%2.36M | -22.01%581K | -17.35%581K | -6.76%579K | -3.28%619K | 32.02%2.71M | 23.34%745K | 31.40%703K | 25.20%621K |
Other net income (expense) | -11.15%-12.16M | 31.57%-37.83M | 25.64%-26.64M | 82.73%-916K | 103.95%665K | -504.77%-10.94M | -34.88%-55.28M | -168.99%-35.82M | 76.07%-5.3M | 76.48%-16.86M |
Gain on sale of security | -202.47%-1.1M | 62.50%4.75M | 182.72%1.32M | 207.49%1.71M | 163.40%2.09M | -103.88%-365K | 104.54%2.93M | -185.63%-1.6M | 87.75%-1.59M | 94.80%-3.3M |
Special income (charges) | 10.89%-12.22M | 19.93%-50.86M | 23.84%-28.34M | -15.32%-4.35M | 71.51%-4.46M | -98.58%-13.71M | -374.47%-63.52M | -173.50%-37.2M | 59.60%-3.77M | -82.83%-15.65M |
-Less:Restructuring and merger&acquisition | --8.89M | ---- | ---- | --976K | ---- | --0 | ---- | ---- | --0 | ---- |
-Less:Other special charges | -69.07%3.15M | -0.67%50.86M | -10.32%33.66M | -14.79%3.2M | 26.64%3.82M | 47.57%10.18M | 25.96%51.2M | 247.29%37.54M | -59.42%3.75M | -67.16%3.01M |
-Gain on sale of property,plant,equipment | 94.74%-186K | --0 | 1,210.84%4.35M | -826.32%-176K | 94.93%-640K | -39,188.89%-3.54M | -119.31%-12.32M | -99.46%332K | 78.16%-19K | -2,133.98%-12.63M |
Other non- operating income (expenses) | -62.91%1.16M | 55.70%8.27M | -87.34%377K | 2,928.07%1.73M | 45.47%3.03M | 1,453.47%3.14M | 2,000.40%5.31M | 634.65%2.98M | -61.22%57K | 953.03%2.09M |
Income before tax | 495.37%51.77M | 284.57%126.35M | 430.62%56.27M | 596.64%74.56M | 138.21%8.62M | 5.66%-13.09M | -7.89%-68.46M | -134.97%-17.02M | 72.98%-15.01M | 65.80%-22.55M |
Income tax | 14.91%18.41M | 91.86%67.45M | 117.09%18.42M | 323.44%25.82M | -27.13%7.19M | 49.65%16.02M | 139.84%35.16M | 2,115.44%8.49M | 223.79%6.1M | -14.22%9.87M |
Net income | 214.55%33.35M | 156.85%58.9M | 248.41%37.85M | 330.89%48.74M | 104.40%1.43M | -18.43%-29.12M | -32.65%-103.61M | -151.96%-25.51M | 63.25%-21.11M | 58.14%-32.41M |
Net income continuous Operations | 214.55%33.35M | 156.85%58.9M | 248.41%37.85M | 330.89%48.74M | 104.40%1.43M | -18.43%-29.12M | -32.65%-103.61M | -151.96%-25.51M | 63.25%-21.11M | 58.14%-32.41M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 214.55%33.35M | 156.85%58.9M | 248.41%37.85M | 330.89%48.74M | 104.40%1.43M | -18.43%-29.12M | -32.65%-103.61M | -151.96%-25.51M | 63.25%-21.11M | 58.14%-32.41M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 214.55%33.35M | 156.85%58.9M | 248.41%37.85M | 330.89%48.74M | 104.40%1.43M | -18.43%-29.12M | -32.65%-103.61M | -151.96%-25.51M | 63.25%-21.11M | 58.14%-32.41M |
Basic earnings per share | 175.00%0.06 | 150.00%0.15 | 266.67%0.1 | 300.00%0.12 | 103.62%0.0036 | 0.00%-0.08 | -7.14%-0.3 | -131.58%-0.06 | 71.43%-0.06 | 64.29%-0.1 |
Diluted earnings per share | 175.00%0.06 | 150.00%0.15 | 266.67%0.1 | 300.00%0.12 | 103.57%0.0036 | 0.00%-0.08 | -7.14%-0.3 | -131.58%-0.06 | 71.43%-0.06 | 64.29%-0.1 |
Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |